TOP MKENA SECRETS

CDER’s latest proposal to withdraw the accelerated acceptance of Makena (HPC) was based on a substantial randomized demo that failed to confirm the advantage of this drug to newborns or decrease the risk of PTB. In creating the choice to suggest Makena’s withdrawal, CDER also reviewed outcomes from prior scientific studies of progestins (HPC